Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 1122  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Article Submission Resources Sections Etcetera Contact
 
  NAVIGATE Here 
  Search
 
 :: Next article
 :: Previous article 
 :: Table of Contents
  
 RESOURCE Links
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::Related articles
 ::  Article in PDF (234 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
   Abstract
   True pathogenic ...
   Opportunistic fungi
   Conclusion
   References
   Article Tables

 Article Access Statistics
    Viewed18858    
    Printed341    
    Emailed19    
    PDF Downloaded1138    
    Comments [Add]    
    Cited by others 22    

Recommend this journal


 


 
REVIEW ARTICLE
Year : 2005  |  Volume : 51  |  Issue : 5  |  Page : 16-20

Microbiology of systemic fungal infections


Department of Medical Microbiology Postgraduate Institute of Medical Education & Research, Chandigarh, India

Correspondence Address:
A Chakrabarti
Department of Medical Microbiology Postgraduate Institute of Medical Education & Research, Chandigarh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 16519250

Rights and PermissionsRights and Permissions


  Abstract 

The increased incidence of systemic fungal infections in the past two decades has been overwhelming. Earlier, it was pathogenic dimorphic fungi, which were known to cause systemic infections. However, starting from the 1960s, opportunistic fungi started causing more number of infections, especially in the immunocompromised host. More recently, newer and less common fungal agents are being increasingly associated with infection in immunosuppressed hosts. Amongst dimorphic fungi, infections due to Histoplasma capsulatum and Penicillium marneffei are increasingly reported in patients with AIDS in India. H. capsulatum is found country wide, but P. marneffei remains restricted to Manipur state. Although both varieties of C. neoformans , C. neoformans var. neoformans (serotypes A & D), and C. neoformans var. gattii (serotypes B & C) are reported in India, most of the cases reported are of serotype A. Increased incidence of cryptococcosis is reported from all centers with the emergence of AIDS. Systemic infection due to species under Candida , Aspergillus and zygomycetes is widely prevalent in nosocomial setting, and outbreaks due to unusual fungi are reported occasionally from tertiary care centers. This global change in systemic fungal infections has emphasized the need to develop good diagnostic mycology laboratories in this country and to recognize this increasingly large group of potential fungal pathogens.


Keywords: Aspergillus, Candida, disseminated fungal infections, fungi, opportunistic infections, systemic fungal infections, Zygomycetes


How to cite this article:
Chakrabarti A, Shivaprakash M R. Microbiology of systemic fungal infections. J Postgrad Med 2005;51, Suppl S1:16-20

How to cite this URL:
Chakrabarti A, Shivaprakash M R. Microbiology of systemic fungal infections. J Postgrad Med [serial online] 2005 [cited 2019 Sep 22];51, Suppl S1:16-20. Available from: http://www.jpgmonline.com/text.asp?2005/51/5/16/19809


Systemic infections caused by fungi constitute a major public health problem in many parts of the world, both in developed and developing countries. Historically, the discovery of the etiologic role played by fungi in disease marked the very beginning of medical microbiology. The founder of the doctrine of pathogenic microbes was Agostino Bassi, a predecessor of Pasteur and Koch. In 1835, Bassi revealed a mold, Beauvaria bassiana , that caused devastating silkworm disease. It was quickly followed by the first discoveries of human disease caused by fungi e.g. favus by Remark and Schoenlein in 1837 and 1842, respectively, candidiasis by Gruby in 1842 and aspergillosis by Sluyter in 1847.[1],[2]

Fungi are extremely fit for survival as evidenced by their ubiquity in nature. However, of the estimated several hundred thousand species of fungi, fewer than 150-200 were considered to be pathogens of humans. However, in recent years, fungi are flourishing in man. The number of fungi causing systemic disease is growing and the number of systemic diseases caused by fungi is increasing. Up to 7% patients dying in teaching hospitals have invasive aspergillosis.[3],[4] Candida spp. accounts for 8-15% of nosocomial blood stream infections and fourth most common isolate of patients of intensive care unit.[5] Specific patient groups have very high frequencies of fungal infections: 15% of allogenic hemopoietic stem-cell transplant recipients have a fungal infection[6]; about 20% of lung transplant recipients are colonized and infected[7]; about 60% and 20% of AIDS patients have Pneumocystis carinii ( jiroveci ) pneumonia or esophageal candidiasis, respectively[8]; cryptococcal meningitis is present in 30% of people with AIDS in Africa and southeast Asia[9]; and Penicillium marneffei infections are present in about 30% of people with AIDS in south-east Asia.[10]

The data on burden of systemic fungal infections in India are not clear though the climatic diversity in this country is suited for a wide variety of fungal infections. However, a definite rising trend has been noted. The systemic fungal infections reported in India are included in [Table - 1].

From our center, an eleven-fold increase in candidemia was reported in the second half of the 1980s[11] and further 18-fold rise was observed in the first half of the 1990s.[12] Fungemia due to unusual yeast - Pichia anomala - was reported from the same center affecting 379 neonates and children (4.2% of all admission) over a period of 23 months.[13] Systemic aspergillosis also caused havoc as 95 patients developed intracranial aspergillosis during 1980-1993.[14] A rising trend in invasive zygomycosis was reported when 129 cases were diagnosed over the period 1990-1999[15] with the emergence of Apophysomyces elegans infection in India.[16] The annual incidence of cryptococcosis has increased about 15-fold compared to pre-AIDS era.[17] All these figures denote that at present a vast array of fungi are causing systemic disease in a large number of patients. Many factors account for this substantial increase in systemic fungal infections, including better management of other complications of immunosuppression, novel and more aggressive immunosuppressive regimens, enhanced survival in intensive care, a high frequency of instrumentation and catheterization, greater awareness of clinicians, better diagnostic approaches, and increased use of broad spectrum antibiotics.

The etiology of systemic fungal infections can be broadly classified into two groups: endemic mycoses due to true pathogenic fungi and opportunistic fungal infections due to a vast array of saprophytic fungi.


  True pathogenic fungi Top


True pathogenic fungi produce a different form in tissue or at 37°C in contrast to mycelial form in culture at 25-30°C. These fungi are referred to as dimorphic fungi and include Histoplasma capsulatum, Histoplasma duboisii, Blastomyces dermatitidis, Coccidioides immitis, Paracoccidioides brasiliensis, Penicillium marneffei , and Sporothrix schenckii. These fungi are usually geographically restricted. C. immitis is a geophilic mold confined to new world and adapted to live specifically in the desert-like terrain of North, Central, and South America.[18] P. marneffei is restricted to south-east Asia possibly remaining with its habitat bamboo rats.[10],[19] H. capsulatum and B. dermatitidis have a worldwide distribution. In India, histoplasmosis and blastomycosis are reported from different states, but penicilliosis marneffei is restricted to Manipur state. There is only one report of systemic sporotrichosis due to S. schenckii var. luriei and represents the only report from an Asian country.[20] Along with emergence of AIDS in India, histoplasmosis is increasingly reported.


  Opportunistic fungi Top


Starting in the 1960s, species under Candida, Aspergillus, Cryptococcus , and zygomycetes began to be regularly associated with patients receiving treatment for cancer, sarcoidosis, diabetes, and organ transplant. The 'big four' of these opportunists were then accounting for more pathology and more investigators' attention than all other fungi combined. However, in the last 30-40 years changes have occurred, and newer pathogens are being recognized especially with the emergence of AIDS. Sometimes, it is not just a single fungus, but rather a combination of fungi i.e. species under Pneumocystis, Candida, Cryptococcus, Histoplasma, Coccidioides, Aspergillus, and zygomycetes, which may produce concomitant and/or successive opportunistic systemic fungal infections. Besides, a long list of less common fungal pathogens is being isolated regularly from clinical specimens. This leads to difficulty in classifying and studying this group of fungal infections. To resolve this problem, Ajello et al. proposed the term "phaeohyphomycosis' to cover all "infections of a cutaneous, subcutaneous, and systemic nature caused by hyphomycetous fungi that develop in host tissues in the form of dark-walled dematiaceous septate mycelial elements"[21] and the name "hyalohyphomycosis" was proposed by Ajello and McGinnis to accommodate mycotic infections in which the tissue form of the etiological agents is septate hyphae with no pigment in the wall.[22]

Candida spp

The overall increase in candidemia in recent years is complicated by the emergence of non- C. albicans Candida (NAC) species as both colonizers and pathogens causing nosocomial fungal blood stream infection (BSI). Wingard in a comprehensive review of all published reports during 1952-1992 found that 12 reports showed proportionally higher (>50%) isolation of NAC species.[23] The NAC species isolated were C. glabrata, C. krusei, C. tropicalis , and C. parapsilosis . Other species like C. guilliermondii, C. lusitaniae, C. dubliniensis, C. kefyr, C. lipolytica , and C. pelliculosa were occasionally isolated. The earliest population-based surveillance study conducted in 1992-1993 by CDC, USA, reported C. albicans as the most common species, followed in order by C. parapsilosis, C. tropicalis , and C. glabrata . Subsequent surveillance programs noted an increase in the proportion of Candida BSI by NAC species and especially an increase in the frequency of BSI due to C. glabrata .[5] In contrast, surveillance data from other countries continue to reflect the importance of C. parapsilosis over C. glabrata .[24]

The importance of patient age in determining rank order of Candia species causing BSI has also been noted.[23] The predominance of C. albicans and C. parapsilosis and the lack of C. glabrata and other NAC species have been observed in neonatal age groups. In contrast, C. glabrata becomes an increasingly important pathogen with increase in age. The contribution of individual NAC species also varies with patients and diagnostic groups. Candidemia due to C. parapsilosis is generally associated with catheters, hyperalimentation, or prosthetic devices.[25] Also, C. parapsilosis is the most common species of Candida to be isolated from the hands of health care workers in ICU, especially those who wear gloves.[26] Thus, it is likely that the contamination of prosthetic devices with the organism occurs via the hand of health care workers. C. glabrata tends to affect oncology patients with solid tumor.[27] C. krusei is intrinsically resistant to fluconazole and increased infection with this organism has been reported in some bone marrow transplant units when fluconazole prophylaxis has been used.[28] Independent of antifungal prophylaxis, C. krusei infection is found predominantly in patients with hematological malignancies, whereas the incidence of C. krusei infections in patients with solid tumor and ICU patients is low.[29]

Similar to the western world, the rise in frequency of NAC species has been observed in tertiary care centers in India as well with isolation rates ranging from 52 to 96%. However, the predominant isolation of C. tropicalis instead of C. glabrata or C. parapsilosis in all age groups in the Indian scenario is unique in this context.[12],[30],[31],[32] The data summarized in [Table - 2] show the worldwide isolation of Candida species from patients with candidemia.

Other yeasts

Cryptococcosis is reported with increasing frequency after the emergence of AIDS.[17] Although a decline in incidence has been observed in developed countries after tri-drug regimen, no such change is seen in developing countries due to poor affordability of the costly drugs. Several other saprophytic yeasts are reported to cause systemic infections in recent years. Those are listed in [Table - 3].

Aspergillus spp. and other moniliaceous fungi

Systemic aspergillosis is the second most common invasive fungal infections. In certain patient groups, such as hematological malignancies, the condition has been reported as accounting for up to 30% of patients in postmortem series[34] and 36% of patients with pneumonia in bone-marrow transplant unit.[35] Data gathered between 1980 and 1990 in a cross-section of hospitals throughout USA indicated that 1.3% of all nosocomial infections were caused by Aspergillus s pecies.[36]

A. fumigatus is the most common cause of invasive aspergillosis. A. flavus , the second most common species, is isolated from systemic aspergillosis of immunosuppressed patients, as well as from lesions originating from the nasal sinuses. However, in India, Sudan, and South Africa, A. flavus is the most common cause of all forms of aspergillosis. A. niger is the third most common cause of invasive aspergillosis. Other species documented rarely include A. nidulans, A. versicolor, A. candidus, A. oryzae, A. sydowii, A. terreus, A. clavatus , etc.

Fusarium species, cosmopolitan soil saprobe, can cause systemic infection in humans. Increased incidence, often with fatal outcome, has been seen in neutropenic patients with hematological malignancies and in patients with bone-marrow and solid-organ transplantation.[37] Other rare systemic infections are reported due to fungi belonging to genera Scedosporium, Pseudallescheria, Acremonium, Lecythophora, Phialemonium, Phaeoacremonium, Paecilomyces and Emmonsia .

Zygomycetes

Like Aspergillus species, zygomycetes are common nosocomial pathogens to cause systemic zygomycosis. However, the exact incidence is difficult to ascertain due to difficulty in ante-mortem diagnosis. Systemic zygomycosis can also be community acquired especially in patients with uncontrolled diabetes mellitus, other forms of metabolic acidosis, burns, and malignant hematological disorders.

Many different zygomycetes have been implicated, but the most common causes of systemic zygomycosis, listed in order of apparent incidence, are Rhizopus arrhizus and Rhizopus microsporus var. rhizopodoformis . Other less frequent etiological agents, but for which a major pathogenic role in humans has been established, include Absidia corymbifera , Apophysomyces elegans , Cunninghamella bertholletiae , Mucor species, Rhizomucor pusillus , and Saksenaea vasiformis . These molds are ubiquitous and thermotolerant and can be isolated in large numbers from soil or decomposing organic matter, such as fruit and bread. The spores can often be found in hospital and outside air.

Dematiaceous fungi

Dematiaceous fungi often are thought of as being exclusively hyphomycetes, but some ascomycetes, basidiomycetes, and zygomycetes are also dematiaceous by the presence of a brown or black color in the cell wall. It has been suggested that the term "dematiaceous" is a misnomer and the term "phaeoid" should be used as a replacement.[38]

Although Ajello et al .[21] proposed the term "phaeohyphomycosis" to cover all infections caused by hyphomycetous fungi having dark-walled dematiaceous septate mycelial elements in tissue, it presently encompasses all fungi having dematiaceous cells in infected tissue, regardless of the taxonomic classification of the etiological agent. More than 100 species of fungi can cause systemic infection, but the disease is still rare.

Pneumocystis sp .

In the late 1980s, phylogenetic analyses based on the nuclear small-subunit rRNA sequence alignments showed conclusively that P. carinii is a member of the fungal kingdom.[39] P. carinii was thought to represent a single zoonotic species. However, it is now clear that the organism first identified as " P. carinii" is actually a family of related organisms that exhibit mammalian host specificity. The first species of Pneumocystis f or human-derived organisms, is now known as P. jiroveci replacing P. carinii f. sp. hominis.[40]

P. jiroveci is a leading agent to cause pneumonia in AIDS and other immunocompromised states. However, it can cause systemic infection as well. The incidence of Pneumocystis infection in sites other than lung has been reported to be 1-3% in postmortem examinations of patients with pulmonary Pneumocystis infection.[41],[42] This is likely an underestimate due to the lack of suspicion of extra-pulmonary pneumocystosis. The lymph modes were the most frequent site (44%) of extra-pulmonary infection in that series of 52 patients followed by the spleen, bone marrow, and liver (33%). It is also detected in the adrenal glands, gastrointestinal tract, genitourinary tract, thyroid, ear, pancreas, eyes, skin, and other sites.[41]


  Conclusion Top


This review emphasizes the fact that the clinical mycology laboratory must be able to recognize this increasingly large group of potential pathogens. Organisms once thought to be contaminants are now confirmed pathogens causing systemic infection in immunocompromised patients. In addition, there is a critical need to recognize that even though a given isolate may not be a documented fungal pathogen in textbooks, its isolation from a normally sterile site and its ability to grow at 37°C require that it be considered a possible pathogen.

 
  References Top

1.Kisch B. Forgotten leaders in modern medicine: Valentin, Gruby, Remark, Auerback. Trans Am Philos Soc 1954;44:139-317.  Back to cited text no. 1    
2.Ajello L. Systemic mycoses in modern medicine. Contr Microbiol Immunol 1977;3:2-6.  Back to cited text no. 2    
3.Groll AH, Shah PM, Mentzel C,Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of fungal infections at a University hospital. J Infect 1996;33:23-32.  Back to cited text no. 3  [PUBMED]  
4.Vogesar M, Hass A, Aust D, Ruckdeschel G. Postmortem analysis of invasive aspergillosis in a tertiary care hospital. Eur J Clin Microbiol Inf Dis 1997;16:1-6.  Back to cited text no. 4    
5.Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: Trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002;40:3551-7.  Back to cited text no. 5    
6.Ribaud P, Chastang C, Latge JP, et al . Outcome and prognostic factors of invasive aspergillosis after allogenic bone marrow transplantation. Clin Infect Dis 1999;28:322-30.  Back to cited text no. 6    
7.Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781-805.  Back to cited text no. 7  [PUBMED]  
8.Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV infected urban clinical cohort. Ann Intern Med 1996;124:633-42.  Back to cited text no. 8  [PUBMED]  [FULLTEXT]
9.Grant AD, Djomand G, DeCock KM. Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS 1997;11:S43-54.  Back to cited text no. 9    
10.Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994;344:110-3.  Back to cited text no. 10  [PUBMED]  
11.Chakrabarti A, Chander J, Kasturi P, Panigrahi D. Candidemia: a 10-year study in an Indian teaching hospital. Mycoses 1992;35:47-51.  Back to cited text no. 11  [PUBMED]  
12.Chakrabarti A, Ghosh A, Batra R, Kaushal A, Roy P, Singh H. Antifungal susceptibility pattern of non-albicans Candida species and distribution of species isolated from candidemia cases over a 5 year period. Indian J Med Res 1996;104:171-6.  Back to cited text no. 12  [PUBMED]  
13.Chakrabarti A, Singh K, Narang A, et al . Outbreak of Pichia anomala infection in the pediatric service of a tertiary care centre in northern India. J Clin Microbiol 2001;39:1702-6.  Back to cited text no. 13    
14.Sharma BS, Khosla VK, Kak VK, et al . Intra-cranial fungal granuloma. Surg Neurol 1997;47:489-97.  Back to cited text no. 14    
15.Chakrabarti A, Das A, Sharma A, et al . Ten years' experience in zygomycosis at a tertiary care centre in India. J Infect 2001;42:261-6.  Back to cited text no. 15    
16.Chakrabarti A, Ghosh A, Prasad GS, et al . Apophysomyces elegans : an emerging zygomycetes in India. J Clin Microbiol 2003;41:783-8.  Back to cited text no. 16    
17.Chakrabarti A, Sharma A, Sood A, et al. Changing scenario of cryptococcosis in a tertiary care hospital in north India. Indian J Med Res 2000;112:56-60.  Back to cited text no. 17    
18.Ajello L. Comparative ecology of respiratory mycotic disease agents. Bact Rev 1967;31:6-24.  Back to cited text no. 18    
19.Ranjana KH, Priyokumar K, Singh TJ, et al . Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect 2002;45:268-71.  Back to cited text no. 19    
20.Padhye AA, Kaufman L, Durry E, et al . Fatal pulmonary sporotrichosis caused by Sporothrix schenckii var. luriei in India. J Clin Microbiol 1992;30:2492-4.  Back to cited text no. 20    
21.Ajello L. The gamut of human infections caused by dematiaceous fungi. Jpn J Med Mycol 1981;22:1-5.  Back to cited text no. 21    
22.Ajello L, McGinnis MR. Nomenclature of human pathogenic fungi. In Grundlagen der Antiseptik: Part 4. Factoren der Mikrobiellen Kolonisation. Edited by A. P. Krasilnikow et al . Berlin: Verlag Volk und Gesundheit; 1984, p.363-77.  Back to cited text no. 22    
23.Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115-25.  Back to cited text no. 23    
24.Chryssanthon E. Trends in antifungal susceptibility among Swedish Candida species blood stream isolates from 1994-1998: comparison of the E-test and the sensitive yeast on colorimetric antifungal panel with NCCLS M27-A reference method. J Clin Microbiol 2001;39:4181-3.  Back to cited text no. 24    
25.Weem JJ Jr., Chamberland ME, Ward J, Willy M, Padhye AA, Solomon SL. Candida parapsiolosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers. J Clin Microbiol 1987;25:1029-32.  Back to cited text no. 25    
26.Rangel - Frausto MS, Wiblin T, Blumberg HM, et al . National epidemiology of mycoses survey (NEMIS): variation in rates of blood stream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999;29:253-8.  Back to cited text no. 26    
27.Kno AS, Brnadt ME, Pruitt WR, et al . The epidemiology of candidemia in two United States cities: result of a population based active surveillance. Clin Infect Dis 1999;29:1164-70.  Back to cited text no. 27    
28.Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogenic blood and marrow transplant recipients: evaluation of risk factors after adoption of prophylactic fluconazole. J Infect Dis 2000;181:309-16.  Back to cited text no. 28    
29.Viscoli C, Girmenia C, Maxinus A, et al . Candidemia in cancer patients. A prospective, multicentre surveillance studies in Europe by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research & Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071-9.  Back to cited text no. 29    
30.Chakrabarti A, Mohan B, Shrivastava SK, Marak RS, Ghosh A, Ray P. Change in distribution and antifungal susceptibility of Candida species isolated from candidemia cases in a tertiary care center during 1996-2000. Indian J Med Res 2002;116:5-12.  Back to cited text no. 30    
31.Rani R, Mohapatra NP, Mehta G, Randhawa VS. Changing trends of Candida species in neonatal septicaemia in a tertiary north Indian hospital. Indian J Med Res 2002;116:42-4.  Back to cited text no. 31    
32.Verma AK, Prasad KN, Singh M, Dixit AK, Ayyagari A. Candidemia in patients of a tertiary health care hospital from north India. Indian J Med Res 2003;117:122-8.  Back to cited text no. 32    
33.Hobson RP. The global epidemiology of invasive Candida infection - is the tide turning? J Hosp Infect 2003;55:159-68.  Back to cited text no. 33    
34.Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients and international autopsy survey. Eur J Clin Microbiol 1992;11:99-109.  Back to cited text no. 34    
35.Pannuti CS, Gingrich RD, Pfaller MA, Wenzel RP. Nosocomial pneumonia in adult patients undergoing bone-marrow transplantation: a 9-year study. J Clin Oncol 1991;9:77-84.  Back to cited text no. 35    
36.Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996;9:499-511.  Back to cited text no. 36    
37.Guarro J, Gene J. Opportunistic fusarial infections in human. Eur J Clin Microbiol Infect Dis 1995;14:741-54.  Back to cited text no. 37    
38.Pappagianis D, Ajello L. Dematiaceous - a mycologic misnomer? J Med Vet Mycol 1994;32:319-21.  Back to cited text no. 38    
39.Edman JC, Kovacs JA, Masur H, Edman U. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988;334:519-22.  Back to cited text no. 39    
40.Frenkel JK. Pneumocystis pneumonia, an immunodeficiency dependent disease (IDD): a critical historical overview (with a latin rediscription of Pneumocystis jiroveci of humans in conformance with the International code of Botanical Nomenclature). J Eucaryot Microbiol 1999;46:89S-92S.  Back to cited text no. 40    
41.Telzak EE, Armstrong D. Extrapulmonary infection and other unusual manifestations of Pneumocystis carinii . In P.D. Walzer (Ed.) Pneumocystis carinii pneumonia. 2nd Edn. Marcel Dekker: New York, NY; 1994, p.361-80.  Back to cited text no. 41    
42.Ng VL, YajKo DM, Hadley WK. Extrapulmonary pnumocystosis. Clin Microbiol Rev 1997;10:401-18.  Back to cited text no. 42    


    Tables

[Table - 1], [Table - 2], [Table - 3]

This article has been cited by
1 Additive effect of rPb27 immunization and chemotherapy in experimental paracoccidioidomycosis
Fernandes, V.C., Martins, E.M.N., Boeloni, J.N., Coitinho, J.B., Serakides, R., Goes, A.M.
PLoS ONE. 2011; 6(3): art 17885
[Pubmed]
2 Antifungal agents, WO2009025733
Sudhir, P.V., Ranjan, D.S., Ganpat, A.N.
Expert Opinion on Therapeutic Patents. 2010; 20(1): 137-143
[Pubmed]
3 HSP65 DNA as therapeutic strategy to treat experimental paracoccidioidomycosis
Ribeiro, A.M., Bocca, A.L., Amaral, A.C., Souza, A.C.C.O., Faccioli, L.H., Coelho-Castelo, A.A.M., Figueiredo, F., Felipe, M.S.S.
Vaccine. 2010; 28(6): 1528-1534
[Pubmed]
4 Mesenteric cryptococcal lymphadenitis. Report of one case | [Linfoadenitis criptococócica mesentérica: Una rara causa de abdomen agudo. Caso clínico]
Oscar Tapia, E., Miguel Villaseca, H., Juan Carlos Araya, O.
Revista Medica de Chile. 2010; 138(12): 1535-1538
[Pubmed]
5 Development of amphotericin B loaded polymersomes based on (PEG)3-PLA co-polymers: Factors affecting size and in vitro evaluation
Jain, J.P., Kumar, N.
European Journal of Pharmaceutical Sciences. 2010; 40(5): 456-465
[Pubmed]
6 Microbial etiology of febrile neutropenia
Swati, M., Gita, N., Sujata, B., Farah, J., Preeti, M.
Indian Journal of Hematology and Blood Transfusion. 2010; 26(2): 49-55
[Pubmed]
7 Natural products as antifungal agents against clinically relevant pathogens
Di Santo, R.
Natural Product Reports. 2010; 27(7): 1084-1098
[Pubmed]
8 Studies on peptidyl nucleoside antibiotics: Synthesis and antifungal evaluation of pyranosyl nucleoside analogs of nikkomycin
Stauffer, C.S., Fothergill, A.W., Rinaldi, M.G., Dutta, A.
Future Medicinal Chemistry. 2009; 1(2): 379-389
[Pubmed]
9 Antimicrobial effect of farnesol, a Candida albicans quorum sensing molecule, on Paracoccidioides brasiliensis growth and morphogenesis
Derengowski, L.S., De-Souza-Silva, C., Braz, S.V., Mello-De-Sousa, T.M., Báo, S.N., Kyaw, C.M., Silva-Pereira, I.
Annals of Clinical Microbiology and Antimicrobials. 2009; 8(Art 13)
[Pubmed]
10 Survey of opportunistic fungi in ocular infection in the Eastern Province of Saudi Arabia
Alqurashi, A.M.
Journal of Food, Agriculture and Environment. 2009; 7(2): 247-251
[Pubmed]
11 Recent progress in the discovery of macrocyclic compounds as potential anti-infective therapeutics
Obrecht, D., Robinson, J.A., Bernardini, F., Bisang, C., DeMarco, S.J., Moehle, K., Gombert, F.O.
Current Medicinal Chemistry. 2009; 16(1): 42-65
[Pubmed]
12 In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi
González, G.M.
Medical Mycology. 2009; 47(1): 71-76
[Pubmed]
13 New advances in fatty acids as antimalarial, antimycobacterial and antifungal agents
Carballeira, N.M.
Progress in Lipid Research. 2008; 47(1): 50-61
[Pubmed]
14 I. Introduction. Current status of medical mycology in Mexico | [I. Introducción. Importancia actual de la micología médica en México]
López-Martínez, R.
Gaceta Medica de Mexico. 2008; 144(2): 121-122
[Pubmed]
15 The use of MUC5B antibody in identifying the fungal type of fungal sinusitis
Piao, Y.-S., Zhang, Y., Yang, X., He, C.-Y., Liu, H.-G.
Human Pathology. 2008; 39(5): 650-656
[Pubmed]
16 Current status of medical mycology in Mexico - Introduction
Lopez-Martinez R
GACETA MEDICA DE MEXICO. 2008; 144(2): 121-122
[Pubmed]
17 Significance of MUC5B antibody in differential diagnosis between Aspergillus species and Mucorales of fungal sinusitis
Piao, Y.-S., Liu, H.-G., Liu, X.-J.
Chinese Journal of Pathology. 2008; 37(4): 255-258
[Pubmed]
18 Recent patents in antifungal agent discovery
Di Santo, R.
Expert Opinion on Therapeutic Patents. 2008; 18(3): 275-292
[Pubmed]
19 Opportunistic mycoses among immunosupressed patients
Mercado EVD, Arenas R
GACETA MEDICA DE MEXICO. 2008; 144(2): 131-133
[Pubmed]
20 Effect of a novel phyto-compound on mucosal candidiasis: Further evidence from an ex vivo study
Nakajima, J., Papaah, P., Yoshizawa, M., Marotta, F., Nakajima, T., Mihara, S., Minelli, E.
Multiphase Pumping and Technologies Conference and Exhibition 2007. 2007; 8(1): 48-51
[Pubmed]
21 Fungal infections in HIV-positive patients with dyspepsia | [Zakazenia grzybicze u pacjentów HIV-dodatnich z objawami dyspepsji]
Macura, A.B., Mach, T., Skwara, P., Pawlik, B.
Mikologia Lekarska. 2007; 14(3): 185-189
[Pubmed]
22 Recent developments in antifungal drug discovery
Di Santo R
ANNUAL REPORTS IN MEDICINAL CHEMISTRY. 2006; 41: 299-315
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article
Online since 12th February '04
© 2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow